OCT 09, 2019 12:00 PM PDT

Next Steps in Personalized Medicine- Using Genomics and Imaging For Treatment Selection in Early Stage Prostate Cancer

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Medical Science Liaison (Urology), Genomic Health, Inc.
    Biography
      Anson Tharayanil graduated from University of California, Davis with a degree in Biological Sciences. With over a decade of experience in the biotechnology space, he has helped bring several multigene signature tests for breast, colon, and prostate cancer into clinical use. His passion is in educating both physicians and patients on the use and value of genomic tests to optimize cancer care.

    Abstract

    This presentation will review the utility of multiparametric MRI (mpMRI) and genomic testing in the management of early stage prostate cancer and show when and if such tests should be used alone or in combination.
    Prostate cancer (PCa) is the second most frequently diagnosed male malignancy worldwide. In the United States, approximately over 174,000 men are diagnosed with PCa and 31,000 men die of the disease per year.  The majority of PCa diagnosed, however, are low-risk indolent lesions which are not expected to increase disease-specific mortality.  Despite evidence demonstrating the lack of prostate cancer specific-survival benefit in this population, many patients receive immediate curative therapy.
     
    Recently, active surveillance (AS), which monitors patients for disease progression, has been included in the National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) guidelines and is increasingly utilized as a treatment option for low- and favorable intermediate-risk patients.  Adoption of AS has been slow as current clinicopathological factors such as patient age, PSA, tumor grade (Gleason score) and tumor volume on biopsy do not adequately risk stratify patients.  
    Newer tools for patient risk stratification such as mpMRI and genomic tests have substantially improved risk stratification so that clinicians can better optimize treatment selection between AS and immediate therapy such as radical prostatectomy or radiation.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    Loading Comments...
    Show Resources
    Attendees
    • See more